Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 360 articles:
HTML format
Text format



Single Articles


    April 2017
  1. KONGTIM P, Adekola K, Milton DR, Ramlal R, et al
    Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Leukemia. 2017 Apr 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  2. HAN SH, Kim SH, Kim HJ, Lee Y, et al
    Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
    Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.
    PubMed     Text format    


  3. JONES D, Woyach JA, Zhao W, Caruthers S, et al
    PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  4. SILVA P, Neumann M, Schroeder MP, Vosberg S, et al
    Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    March 2017
  5. HEROLD S, Kuhn M, Bonin MV, Stange T, et al
    Donor cell leukemia-Evidence for multiple pre-leukemic clones and parallel long term clonal evolution in donor and recipient.
    Leukemia. 2017 Mar 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  6. ANADON C, van Tetering G, Ferreira HJ, Moutinho C, et al
    Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  7. COSSON A, Chapiro E, Bougacha N, Lambert J, et al
    Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  8. MONTALBAN-BRAVO G, Huang X, Naqvi K, Jabbour E, et al
    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format    


  9. WALKER CJ, Eisfeld AK, Genutis LK, Bainazar M, et al
    No evidence for microsatellite instability in acute myeloid leukemia.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  10. KAYSER S, Krzykalla J, Elliott MA, Norsworthy K, et al
    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  11. ZHOU H, Mak PY, Mu H, Mak DH, et al
    Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  12. EISFELD AK, Mrozek K, Kohlschmidt J, Nicolet D, et al
    The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  13. POZZO F, Bittolo T, Vendramini E, Bomben R, et al
    NOTCH1 mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin-1 and ribosome associated components.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  14. YUAN T, Yang Y, Chen J, Li W, et al
    Regulation of PI3K signaling in T cell acute lymphoblastic leukemia: A novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.
    Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  15. POULAIN L, Sujobert P, Zylbersztejn F, Barreau S, et al
    High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
    Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    February 2017
  16. HUSSEIN K, Stucki-Koch A, Gohring G, Kreipe H, et al
    Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukemia with bone marrow fibrosis.
    Leukemia. 2017 Feb 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  17. HAN SH, Kim SH, Kim HJ, Lee Y, et al
    Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
    Leukemia. 2017 Feb 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  18. LEHMANN S, Deneberg S, Antunovic P, Rangert-Derolf A, et al
    Early death rates remain high in high-risk APL. Update from the Swedish acute leukemia registry 1997-2013.
    Leukemia. 2017 Feb 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  19. CHATURVEDI A, Herbst L, Pusch S, Klett L, et al
    Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Leukemia. 2017 Feb 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  20. KOBAYASHI M, Chen S, Bai Y, Yao C, et al
    Phosphatase PRL2 promotes AML1-ETO-induced acute myeloid leukemia.
    Leukemia. 2017 Feb 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  21. HOCHHAUS A, Masszi T, Giles FJ, Radich JP, et al
    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study.
    Leukemia. 2017 Feb 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  22. SUGINO N, Kawahara M, Tatsumi G, Kanai A, et al
    A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
    Leukemia. 2017 Feb 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  23. SHIMA Y, Yumoto M, Katsumoto T, Kitabayashi I, et al
    MLL is essential for NUP98-HOXA9-induced leukemia.
    Leukemia. 2017 Feb 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  24. RATNAPARKHE M, Hlevnjak M, Kolb T, Jauch A, et al
    Genomic profiling of acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis.
    Leukemia. 2017 Feb 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  25. KOBAYASHI S, Kobayashi A, Osawa Y, Nagao S, et al
    Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation.
    Leukemia. 2017 Feb 14. doi: 10.1038/leu.2017.
    PubMed     Text format    


  26. ETXABE A, Lara-Castillo MC, Cornet-Masana JM, Banus-Mulet A, et al
    Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem-cell functionality: A promising novel therapeutic target.
    Leukemia. 2017 Feb 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  27. DANG J, Nance S, Ma J, Cheng J, et al
    AMKL chimeric transcription factors are potent inducers of leukemia.
    Leukemia. 2017 Feb 8. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  28. WANG M, Lindberg J, Klevebring D, Nilsson C, et al
    Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
    Leukemia. 2017 Feb 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  29. COPPE A, Andersson EI, Binatti A, Gasparini VR, et al
    Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach.
    Leukemia. 2017 Feb 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    January 2017
  30. CHANAN-KHAN A, Egyed M, Robak T, de Oliveira FA, et al
    Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
    Leukemia. 2017 Jan 31. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  31. ROSSIG C, Pule M, Altvater B, Saiagh S, et al
    Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  32. MURPHY EJ, Neuberg DS, Rassenti LZ, Hayes G, et al
    Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.
    Leukemia. 2017 Jan 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  33. BRUNETTI L, Di Battista V, Venanzi A, Schiavoni G, et al
    Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: A shared clonal origin.
    Leukemia. 2017 Jan 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  34. RECKEL S, Hamelin R, Georgeon S, Armand F, et al
    Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
    Leukemia. 2017 Jan 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  35. DENG J, Isik E, Fernandes SM, Brown JR, et al
    Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Leukemia. 2017 Jan 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  36. GUIDUGLI L, Johnson AK, Alkorta-Aranburu G, Nelakuditi V, et al
    Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes.
    Leukemia. 2017 Jan 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  37. WATTAD M, Weber D, Dohner K, Krauter J, et al
    Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
    Leukemia. 2017 Jan 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  38. YOSHIDA N, Sakaguchi H, Muramatsu H, Okuno Y, et al
    Germline IKAROS mutation associated with primary immunodeficiency that progressed to T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  39. KAROL SE, Larsen E, Cheng C, Cao X, et al
    Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  40. SCHLENK RF, Frech P, Weber D, Brossart P, et al
    Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.
    Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  41. BACCARANI M
    Treatment-free remission in chronic myeloid leukemia: Floating between expectation and evidence.
    Leukemia. 2017 Jan 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  42. JAHN N, Agrawal M, Bullinger L, Weber D, et al
    Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG).
    Leukemia. 2017 Jan 16. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  43. PEIRS S, Frismantas V, Matthijssens F, Van Loocke W, et al
    Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  44. KELLY AD, Kroeger H, Yamazaki J, Taby R, et al
    A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome.
    Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  45. MEHDIPOUR P, Santoro F, Botrugno OA, Romanenghi M, et al
    HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia.
    Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  46. CUTRONA G, Matis S, Colombo M, Massucco C, et al
    Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy.
    Leukemia. 2017 Jan 5. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  47. LI YJ, Sun L, Shi Y, Wang G, et al
    PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions.
    Leukemia. 2017 Jan 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  48. ISHIYAMA K, Kitawaki T, Sugimoto N, Sozu T, et al
    Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.
    Leukemia. 2017;31:268.
    PubMed     Text format    


    December 2016
  49. ROHRABAUGH S, Kesarwani M, Kincaid Z, Huber E, et al
    Enhanced MAPK signaling is essential for CSF3R induced leukemia.
    Leukemia. 2016 Dec 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  50. ALDOSS I, Bargou RC, Nagorsen D, Friberg GR, et al
    Redirecting T-cells to eradicate B-cell acute lymphoblastic leukemia: Bispecific T-cell engagers and chimeric antigen receptors.
    Leukemia. 2016 Dec 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  51. LIAU WS, Tan SH, Ngoc PC, Wang CQ, et al
    Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
    Leukemia. 2016 Dec 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  52. ARRUGA F, Gizdic B, Bologna C, Cignetto S, et al
    Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22.
    Leukemia. 2016 Dec 26. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  53. PATEL VM, Balakrishnan K, Douglas M, Tibbitts T, et al
    Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
    Leukemia. 2016 Dec 26. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  54. FISHER DA, Malkova O, Engle EK, Miner C, et al
    Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.
    Leukemia. 2016 Dec 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  55. LANG F, Wojcik B, Bothur S, Knecht C, et al
    Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations.
    Leukemia. 2016 Dec 13. doi: 10.1038/leu.2016.
    PubMed     Text format    


  56. TASIAN SK, Hurtz C, Wertheim GB, Bailey NG, et al
    High incidence of philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) in older adults with B-ALL.
    Leukemia. 2016 Dec 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  57. CHARMSAZ S, Al-Ejeh F, Yeadon T, Miller KJ, et al
    EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
    Leukemia. 2016 Dec 6. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  58. VARDI A, Vlachonikola E, Karypidou M, Stalika E, et al
    Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: High-throughput immunoprofiling supports selection by shared antigenic elements.
    Leukemia. 2016 Dec 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  59. YU J, Chen L, Cui B, Wu C, et al
    Cirmtuzumab inhibits Wnt5a-induced Rac1-activation in chronic lymphocytic leukemia treated with ibrutinib.
    Leukemia. 2016 Dec 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    November 2016
  60. VESELY C, Frech C, Eckert C, Cario G, et al
    Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.
    Leukemia. 2016 Nov 30. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  61. ILANDER M, Olsson-Stromberg U, Schlums H, Guilhot J, et al
    Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  62. BISIO V, Zampini M, Tregnago C, Manara E, et al
    NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: A report from the AIEOP-AML group.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  63. YOUNG E, Noerenberg D, Mansouri L, Ljungstrom V, et al
    EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  64. QUINTAS-CARDAMA A, Hu C, Qutub A, Qiu YH, et al
    p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
    Leukemia. 2016 Nov 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  65. THOL F, Klesse S, Kohler L, Gabdoulline R, et al
    Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
    Leukemia. 2016 Nov 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  66. CHIEN W, Sun QY, Ding LW, Mayakonda A, et al
    Diagnosis and relapse: Cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.
    Leukemia. 2016 Nov 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  67. KOBAYASHI M, Bai Y, Chen S, Gao R, et al
    Phosphatase PRL2 promotes oncogenic NOTCH1-induced T cell leukemia.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  68. JOVANOVIC JV, Chillon MC, Vincent-Fabert C, Dillon R, et al
    The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid sensitive acute promyelocytic leukemia.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  69. CERELLA C, Gaigneaux A, Mazumder A, Lee JY, et al
    Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  70. SHEN Y, Park CS, Suppipat K, Mistretta TA, et al
    Inactivation of KLF4 promotes T cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  71. EISFELD AK, Kohlschmidt J, Schwind S, Nicolet D, et al
    Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
    Leukemia. 2016 Nov 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  72. GOLTZ D, Gevensleben H, Grunen S, Dietrich J, et al
    PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  73. BAER C, Dicker F, Kern W, Haferlach T, et al
    Genetic characterization of MYD88 mutated lymphoplasmacytic lymphoma in comparison to MYD88 mutated chronic lymphocytic leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  74. ZHOU C, Martinez E, Di Marcantonio D, Patel-Solanki N, et al
    JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  75. DAFFLON C, Craig VJ, Mereau H, Grasel J, et al
    Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  76. ESTEY E, Gale RP
    Acute myeloid leukemia therapy and the chosen people.
    Leukemia. 2016 Nov 11. doi: 10.1038/leu.2016.
    PubMed     Text format    


  77. VON DER HEIDE EK, Neumann M, Vosberg S, James AR, et al
    Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients.
    Leukemia. 2016 Nov 11. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  78. STAMATOPOULOS K, Agathangelidis A, Rosenquist R, Ghia P, et al
    Antigen receptor stereotypy in chronic lymphocytic leukemia.
    Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  79. GAIDZIK VI, Teleanu V, Papaemmanuil E, Weber D, et al
    RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Leukemia. 2016;30:2282.
    PubMed     Text format    


    October 2016
  80. MONTALBAN-BRAVO G, Huang X, Jabbour E, Borthakur G, et al
    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  81. JULIUSSON G, Abrahamsson J, Lazarevic V, Antunovic P, et al
    Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  82. KHAN N, Hills RK, Virgo P, Couzens S, et al
    Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  83. BERGER G, van den Berg E, Sikkema-Raddatz B, Abbott KM, et al
    Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  84. STAMATOPOULOS B, Timbs A, Bruce D, Smith T, et al
    Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  85. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  86. BARABE F, Gil L, Celton M, Bergeron A, et al
    Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target.
    Leukemia. 2016 Oct 26. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  87. LOHMANN G, Vasyutina E, Bloehdorn J, Reinart N, et al
    Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  88. LARRAYOZ M, Rose-Zerilli MJ, Kadalayil L, Parker H, et al
    Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  89. PARK IK, Blum W, Baker SD, Caligiuri MA, et al
    E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  90. XU B, Zhao Y, Wang X, Gong P, et al
    MZH29 is a novel potent inhibitor that overcomes drug resistance- FLT3 mutations in acute myeloid leukemia.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  91. XIN J, You D, Breslin P, Li J, et al
    Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.
    Leukemia. 2016 Oct 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  92. WU M, Hamaker M, Li L, Small D, et al
    DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.
    Leukemia. 2016 Oct 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  93. NARAYAN N, Morenos L, Phipson B, Willis SN, et al
    Functionally distinct roles foar different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukemia.
    Leukemia. 2016 Oct 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  94. WAANDERS E, Scheijen B, Jongmans MC, Venselaar H, et al
    Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.
    Leukemia. 2016 Oct 13. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  95. MADAN V, Shyamsunder P, Han L, Mayakonda A, et al
    Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
    Leukemia. 2016 Oct 7. doi: 10.1038/leu.2016.
    PubMed     Text format    


  96. KATO M, Ishimaru S, Seki M, Yoshida K, et al
    Long-term outcome of six-month maintenance chemotherapy for acute lymphoblastic leukemia in children.
    Leukemia. 2016 Oct 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  97. VIJAYAKRISHNAN J, Kumar R, Henrion MY, Moorman AV, et al
    A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1.
    Leukemia. 2016 Oct 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    September 2016
  98. NIBOUREL O, Guihard S, Roumier C, Pottier N, et al
    Copy-number analysis identified new prognostic marker in acute myeloid leukemia.
    Leukemia. 2016 Sep 30. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  99. GALLETTI G, Caligaris-Cappio F, Bertilaccio MT
    B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.
    Leukemia. 2016 Sep 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  100. BLUM W, Sanford BL, Klisovic R, DeAngelo DJ, et al
    Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: A phase 2 cancer and leukemia group B study (CALGB 10503).
    Leukemia. 2016 Sep 13. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  101. GEISSLER K, Jager E, Barna A, Alendar T, et al
    Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.
    Leukemia. 2016 Sep 2. doi: 10.1038/leu.2016.
    PubMed     Text format    


  102. THIJSSEN R, Ter Burg J, van Bochove GG, de Rooij MF, et al
    The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
    Leukemia. 2016;30:1963.
    PubMed     Text format    


    August 2016
  103. ALATRASH G, Garber HR, Zhang M, Sukhumalchandra P, et al
    Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.
    Leukemia. 2016 Aug 30. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  104. MIMMI S, Vecchio E, Iaccino E, Rossi M, et al
    Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients.
    Leukemia. 2016 Aug 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  105. GANESAN S, Alex AA, Chendamarai E, Balasundaram N, et al
    Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  106. CHEN Z, Shao C, Wang W, Zuo Z, et al
    Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  107. PUI CH, Pei D, Raimondi SC, Coustan-Smith E, et al
    Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  108. FANG Y, Yang Y, Hua C, Xu S, et al
    Rictor plays a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.
    Leukemia. 2016 Aug 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  109. KONTRO M, Kumar A, Majumder MM, Eldfors S, et al
    HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
    Leukemia. 2016 Aug 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  110. GEISSLER J, Sharf G, Cugurovic J, Padua R, et al
    Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.
    Leukemia. 2016 Aug 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  111. BOYSEN J, Nelson M, Magzoub G, Maiti GP, et al
    Dynamics of microvesicle generation in B cell chronic lymphocytic leukemia: Implication in disease progression.
    Leukemia. 2016 Aug 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  112. KHORASHAD JS, Tantravahi SK, Yan D, Mason CC, et al
    Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.
    Leukemia. 2016 Aug 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  113. HERR W, Eichinger Y, Beshay J, Bloetz A, et al
    HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
    Leukemia. 2016 Aug 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  114. TUBI LQ, Nunes SC, Brancalion A, Breatta ED, et al
    Protein kinase CK2 regulates AKT, NF-kappaB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
    Leukemia. 2016 Aug 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  115. QORRAJ M, Bruns H, Bottcher M, Weigand L, et al
    The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
    Leukemia. 2016 Aug 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    July 2016
  116. ELDFORS S, Kuusanmaki H, Kontro M, Majumder MM, et al
    Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
    Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  117. RUIZ MS, Medina M, Tapia I, Mordoh J, et al
    Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators.
    Leukemia. 2016 Jul 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  118. CRUICKSHANK MN, Ford J, Cheung LC, Heng J, et al
    Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
    Leukemia. 2016 Jul 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  119. CORREIA NC, Arcangeli ML, Pflumio F, Barata JT, et al
    Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.
    Leukemia. 2016 Jul 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  120. EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
    Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.
    Leukemia. 2016 Jul 20. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  121. KOERNER SP, Andre MC, Leibold JS, Kousis PC, et al
    An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
    Leukemia. 2016 Jul 20. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  122. SALEH LM, Wang W, Herman SE, Saba NS, et al
    Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
    Leukemia. 2016 Jul 19. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  123. JONES L, Carol H, Evans K, Richmond J, et al
    A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the pediatric preclinical testing program.
    Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  124. MANARA E, Basso G, Zampini M, Buldini B, et al
    Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.
    Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  125. PING N, Sun A, Song Y, Wang Q, et al
    Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.
    Leukemia. 2016 Jul 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  126. SUN QY, Ding LW, Tan KT, Chien W, et al
    Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).
    Leukemia. 2016 Jul 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  127. THEIS F, Corbacioglu A, Gaidzik VI, Paschka P, et al
    Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: A study of the AML study group (AMLSG).
    Leukemia. 2016 Jul 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    June 2016
  128. ISHIYAMA KI, Kitawaki T, Sugimoto N, Sozu T, et al
    Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.
    Leukemia. 2016 Jun 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  129. ROSE D, Haferlach T, Schnittger S, Perglerova K, et al
    Subtype-specific patterns of molecular mutations in acute myeloid leukemia.
    Leukemia. 2016 Jun 10. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  130. LEE P, Bhansali R, Izraeli S, Hijiya N, et al
    The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with down syndrome.
    Leukemia. 2016 Jun 10. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  131. SCHIFFER CA
    Commentary on: 'Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia'.
    Leukemia. 2016 Jun 10. doi: 10.1038/leu.2016.
    PubMed     Text format    


  132. JAAKO P, Ugale A, Wahlestedt M, Velasco-Hernandez T, et al
    Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.
    Leukemia. 2016 Jun 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  133. RICHINE BM, Virts EL, Bowling JD, Ramdas B, et al
    Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia.
    Leukemia. 2016 Jun 3. doi: 10.1038/leu.2016.
    PubMed     Text format    


    May 2016
  134. RASHIDI A, DiPersio JF, Westervelt P, Vij R, et al
    Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?
    Leukemia. 2016 May 27. doi: 10.1038/leu.2016.
    PubMed     Text format    


  135. HAFERLACH T, Weber S, Konietschke R, Nadarajah N, et al
    Robustness of comprehensive DNA and RNA based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards.
    Leukemia. 2016 May 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  136. CHARAF L, Mahon FX, Lamrissi-Garcia I, Moranvillier I, et al
    Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia (CML) cells.
    Leukemia. 2016 May 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  137. HELLER G, Topakian T, Altenberger C, Cerny-Reiterer S, et al
    Next generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  138. ETCHIN J, Berezovskaya A, Conway AS, Galinsky IA, et al
    KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  139. MITTON B, Chae HD, Hsu K, Dutta R, et al
    Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  140. BASHFORD-ROGERS RJ, Nicolaou KA, Bartram J, Goulden NJ, et al
    Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  141. MCCURDY SR, Iglehart BS, Batista DA, Gocke CD, et al
    Loss of the mismatched human leukocyte antigen haplotype in two acute Myelogenous leukemia relapses after haploidentical bone marrow transplantation with posttransplantation cyclophosphamide.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  142. IMAMURA T, Yano M, Asai D, Moriya-Saito A, et al
    IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance.
    Leukemia. 2016 May 20. doi: 10.1038/leu.2016.
    PubMed     Text format    


  143. CERVANTES-GOMEZ F, Kumar Patel V, Bose P, Keating MJ, et al
    Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Leukemia. 2016 May 20. doi: 10.1038/leu.2016.
    PubMed     Text format    


  144. MORLEY AA
    Reporting results for deep molecular responses in chronic myeloid leukemia.
    Leukemia. 2016 May 17. doi: 10.1038/leu.2016.
    PubMed     Text format    


  145. CROSS NC, Hochhaus A
    Deep molecular response in chronic myeloid leukemia.
    Leukemia. 2016 May 13. doi: 10.1038/leu.2016.
    PubMed     Text format    


  146. CANTE-BARRETT K, Spijkers-Hagelstein JA, Buijs-Gladdines JG, Uitdehaag JC, et al
    MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
    Leukemia. 2016 May 13. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  147. WALLAERT A, Durinck K, Van Loocke W, Van de Walle I, et al
    Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia.
    Leukemia. 2016 May 10. doi: 10.1038/leu.2016.
    PubMed     Text format    


  148. GAIDZIK VI, Teleanu V, Papaemmanuil E, Weber D, et al
    RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Leukemia. 2016 May 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  149. CARDOSO SR, Ryan G, Walne AJ, Ellison A, et al
    Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  150. OTHUS M, Wood BL, Stirewalt DL, Estey EH, et al
    Effect of measurable ("minimal") residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  151. SAUSSELE S, Richter J, Hochhaus A, Mahon FX, et al
    The concept of treatment-free remission in chronic myeloid leukemia.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  152. BRODERSEN LE, Alonzo TA, Menssen AJ, Gerbing RB, et al
    A recurrent immunophenotype at diagnosis independently identifies high risk pediatric acute myeloid leukemia: A report from children's oncology group.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  153. ZHENG Y, Zhang H, Wang Y, Li X, et al
    Loss of Dnmt3b accelerates MLL-AF9 leukemia progression.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  154. HJORTH-HANSEN H, Stentoft J, Richter J, Koskenvesa P, et al
    Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic phase chronic myeloid leukemia patients.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  155. CICCONI L, Divona M, Ciardi C, Ottone T, et al
    PML-RARalpha kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukemia treated with ATRA and ATO or ATRA and chemotherapy.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  156. MAURER C, Langerbeins P, Bahlo J, Cramer P, et al
    Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with chronic lymphocytic leukemia (CLL).
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    April 2016
  157. SONTAKKE P, Carretta M, Jaques J, Brouwers-Vos AZ, et al
    Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold based xenograft model.
    Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  158. HALBACH S, Kohler M, Uhl FM, Huber J, et al
    Gab2 is essential for Bcr-Abl mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.
    Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  159. GEKAS C, D'Altri T, Aligue R, Gonzalez J, et al
    beta-Catenin is required for T cell leukemia initiation and MYC transcription downstream of Notch1.
    Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  160. WATANABE-SMITH K, Tognon C, Tyner JW, Meijerink JP, et al
    Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.
    Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  161. WISEMAN DH, Williams EL, Wilks DP, Leong HS, et al
    Frequent reconstitution of IDH2 mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia.
    Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  162. KONG G, Chang YI, You X, Ranheim EA, et al
    The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent.
    Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  163. WANG Y, Gao A, Zhao H, Lu P, et al
    Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1alpha/CCL3.
    Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  164. DAL BO M, Bulian P, Bomben R, Zucchetto A, et al
    CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
    Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  165. MADAN V, Shyamsunder P, Han L, Mayakonda A, et al
    Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
    Leukemia. 2016 Apr 11. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  166. DARIA D, Kirsten N, Muranyi A, Mulaw M, et al
    GPR56 contributes to the development of acute myeloid leukemia in mice.
    Leukemia. 2016 Apr 11. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  167. YU C, Dasmahapatra G, Dent P, Grant S, et al
    Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
    Leukemia. 2016 Apr 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  168. DINMOHAMED AG, Brink M, Visser O, Jongen-Lavrencic M, et al
    Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013.
    Leukemia. 2016 Apr 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  169. MARIANI SA, Minieri V, De Dominici M, Iacobucci I, et al
    CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia.
    Leukemia. 2016 Apr 5. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  170. BERLIN C, Kowalewski DJ, Schuster H, Mirza N, et al
    Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Leukemia. 2016;30:1003-4.
    PubMed     Text format    


  171. PARDANANI A, Reichard KK, Zblewski D, Abdelrahman RA, et al
    CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value.
    Leukemia. 2016;30:914-8.
    PubMed     Text format     Abstract available


  172. MARTINEZ-MORENO M, Leiva M, Aguilera-Montilla N, Sevilla-Movilla S, et al
    In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by alpha4beta1 cytoplasmic-binding proteins.
    Leukemia. 2016;30:861-72.
    PubMed     Text format     Abstract available


  173. SCHEMIONEK M, Herrmann O, Reher MM, Chatain N, et al
    Mtss1 is a critical epigenetically regulated tumor suppressor in CML.
    Leukemia. 2016;30:823-32.
    PubMed     Text format     Abstract available


  174. WAANDERS E, Hebeda KM, Kamping EJ, Groenen PJ, et al
    Independent development of lymphoid and histiocytic malignancies from a shared early precursor.
    Leukemia. 2016;30:955-8.
    PubMed     Text format    


    March 2016
  175. HUANG W, Luan CH, Hjort EE, Bei L, et al
    The role of Fas-associated phosphatase 1 in leukemia stem cell-persistence during tyrosine kinase inhibitor-treatment of chronic myeloid leukemia.
    Leukemia. 2016 Mar 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  176. TSAI CH, Hou HA, Tang JL, Liu CY, et al
    Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.
    Leukemia. 2016 Mar 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  177. GONDEK LP, Zheng G, Ghiaur G, DeZern AE, et al
    Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
    Leukemia. 2016 Mar 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  178. MATLAWSKA-WASOWSKA K, Kang H, Devidas M, Wen J, et al
    MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: A children's oncology group study.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  179. BRAUN M, Qorraj M, Buttner M, Klein FA, et al
    CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  180. YOUNG SS, Tucker T, Bosdet I, Karsan A, et al
    Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  181. WANG X, Lin Q, Lv F, Liu N, et al
    LG-362B targets PML-RARalpha and blocks ATRA resistance of acute promyelocytic leukemia.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  182. GU Y, Zheng W, Zhang J, Gan X, et al
    Aberrant activation of CaMKIIgamma accelerates chronic myeloid leukemia blast crisis.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  183. HAYAKAWA K, Formica AM, Colombo MJ, Shinton SA, et al
    Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  184. WAGLE M, Eiring AM, Wongchenko M, Lu S, et al
    A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  185. GUNNARSSON N, Hoglund M, Stenke L, Wallberg-Jonsson S, et al
    Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  186. PANG SH, Minnich M, Gangatirkar P, Zheng Z, et al
    PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.
    Leukemia. 2016 Mar 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  187. PINZ K, Liu H, Golightly M, Jares A, et al
    Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.
    Leukemia. 2016;30:701-7.
    PubMed     Text format     Abstract available


  188. HANNA BS, McClanahan F, Yazdanparast H, Zaborsky N, et al
    Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
    Leukemia. 2016;30:570-9.
    PubMed     Text format     Abstract available


  189. SALLMAN DA, Komrokji R, Vaupel C, Cluzeau T, et al
    Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Leukemia. 2016;30:666-73.
    PubMed     Text format     Abstract available


  190. GOYAMA S, Schibler J, Gasilina A, Shrestha M, et al
    UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
    Leukemia. 2016;30:728-39.
    PubMed     Text format     Abstract available


  191. SAITOH Y, Hamano A, Mochida K, Kakeya A, et al
    A20 targets caspase-8 and FADD to protect HTLV-I-infected cells.
    Leukemia. 2016;30:716-27.
    PubMed     Text format     Abstract available


  192. RUMINY P, Marchand V, Buchbinder N, Larson T, et al
    Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia.
    Leukemia. 2016;30:757-60.
    PubMed     Text format    


  193. WU H, Hu C, Wang A, Weisberg EL, et al
    Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
    Leukemia. 2016;30:754-7.
    PubMed     Text format    


    February 2016
  194. LUCAS CM, Milani M, Butterworth M, Carmell N, et al
    High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X in chronic myeloid leukemia.
    Leukemia. 2016 Feb 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  195. ZHOU Y, Othus M, Araki D, Wood BL, et al
    Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
    Leukemia. 2016 Feb 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  196. OTHUS M, Mukherjee S, Sekeres MA, Godwin J, et al
    Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
    Leukemia. 2016 Feb 29. doi: 10.1038/leu.2016.
    PubMed     Text format    


  197. HIRSCH P, Mamez AC, Belhocine R, Lapusan S, et al
    Clonal history of a cord blood donor cell leukemia with pre-natal somatic JAK2 V617F mutation.
    Leukemia. 2016 Feb 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  198. BOBBALA D, Kandhi R, Chen XL, Mayhue M, et al
    Interleukin-15 deficiency promotes the development of T-cell acute lymphoblastic leukemia in non-obese diabetes mice with severe combined immunodeficiency.
    Leukemia. 2016 Feb 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  199. ALVAREZ-TWOSE I, Martinez-Barranco P, Gotlib J, Garcia-Montero A, et al
    Complete response to gemtuzumab-ozogamicin in a patient with refractory mast cell leukemia.
    Leukemia. 2016 Feb 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  200. SOVERINI S, De Benedittis C, Papayannidis C, Polakova KM, et al
    Clinical impact of low burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
    Leukemia. 2016 Feb 12. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  201. KRUG U, Berdel WE, Gale RP, Haferlach C, et al
    Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  202. MIRANDA MB, Lauseker M, Kraus MP, Proetel U, et al
    Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment- long-term observation in CML Study IV.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  203. JAKOBS A, Uttarkar S, Schomburg C, Steinmann S, et al
    An isoform-specific C/EBPbeta inhibitor targets acute myeloid leukemia cells.
    Leukemia. 2016 Feb 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  204. KOHRER S, Havranek O, Seyfried F, Hurtz C, et al
    Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1, and MYC, and can be targeted by SYK inhibition.
    Leukemia. 2016 Feb 5. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  205. CHEN Z, Cortes JE, Jorgensen JL, Wang W, et al
    Differential impact of additional chromosomal abnormalities in myeloid versus lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Leukemia. 2016 Feb 3. doi: 10.1038/leu.2016.
    PubMed     Text format    


  206. HOCHHAUS A, Saglio G, Hughes TP, Larson RA, et al
    Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
    Leukemia. 2016 Feb 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  207. DIELSCHNEIDER RF, Eisenstat H, Mi S, Curtis JM, et al
    Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism.
    Leukemia. 2016 Feb 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  208. RADIVOYEVITCH T, Sachs RK, Gale RP, Molenaar RJ, et al
    Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.
    Leukemia. 2016;30:285-94.
    PubMed     Text format     Abstract available


  209. MUHLBACHER V, Haferlach T, Kern W, Zenger M, et al
    Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis.
    Leukemia. 2016;30:318-24.
    PubMed     Text format     Abstract available


  210. SOLOMON BM, Chaffee KG, Moreira J, Schwager SM, et al
    Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.
    Leukemia. 2016;30:331-6.
    PubMed     Text format     Abstract available


  211. JAYAVELU AK, Muller JP, Bauer R, Bohmer SA, et al
    NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
    Leukemia. 2016;30:473-83.
    PubMed     Text format     Abstract available


  212. MIDDEKE JM, Herbst R, Parmentier S, Bug G, et al
    Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
    Leukemia. 2016;30:261-7.
    PubMed     Text format     Abstract available


  213. KRUPKA C, Kufer P, Kischel R, Zugmaier G, et al
    Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Leukemia. 2016;30:484-91.
    PubMed     Text format     Abstract available


  214. BENEDETTI D, Tissino E, Caldana C, Dal Bo M, et al
    Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?
    Leukemia. 2016;30:513-7.
    PubMed     Text format    


    January 2016
  215. LIM M, Pang Y, Ma S, Hao S, et al
    Altered mesenchymal niche cells impede generation of normal hematopoietic progenitor cells in leukemic bone marrow.
    Leukemia. 2016;30:154-62.
    PubMed     Text format     Abstract available


  216. HERMANOVA I, Arruabarrena-Aristorena A, Valis K, Nuskova H, et al
    Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells.
    Leukemia. 2016;30:209-18.
    PubMed     Text format     Abstract available


  217. CUI X, Zhang L, Magli AR, Catera R, et al
    Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability.
    Leukemia. 2016;30:74-85.
    PubMed     Text format     Abstract available


  218. ETCHIN J, Montero J, Berezovskaya A, Le BT, et al
    Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
    Leukemia. 2016;30:190-9.
    PubMed     Text format     Abstract available


  219. KOCZULA KM, Ludwig C, Hayden R, Cronin L, et al
    Metabolic plasticity in CLL: adaptation to the hypoxic niche.
    Leukemia. 2016;30:65-73.
    PubMed     Text format     Abstract available


  220. NOWEK K, Sun SM, Bullinger L, Bindels EM, et al
    Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
    Leukemia. 2016;30:229-37.
    PubMed     Text format     Abstract available


  221. SAULEP-EASTON D, Vincent FB, Quah PS, Wei A, et al
    The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells.
    Leukemia. 2016;30:163-72.
    PubMed     Text format     Abstract available


  222. SIVE JI, Basilico S, Hannah R, Kinston SJ, et al
    Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia.
    Leukemia. 2016;30:14-23.
    PubMed     Text format     Abstract available


  223. SEVCIKOVA K, Zhuang Z, Garcia-Manero G, Alvarez RH, et al
    Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.
    Leukemia. 2016;30:242-7.
    PubMed     Text format    


    December 2015
  224. MARKE R, Havinga J, Cloos J, Demkes M, et al
    Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.
    PubMed     Text format    


  225. JENA N, Sheng J, Hu JK, Li W, et al
    CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T cell acute lymphoblastic leukemia.
    Leukemia. 2015 Dec 28. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  226. DUTTA S, Krause A, Vosberg S, Herold T, et al
    The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.
    Leukemia. 2015 Dec 21. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  227. CHANG E, Ganguly S, Rajkhowa T, Gocke CD, et al
    The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
    Leukemia. 2015 Dec 21. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  228. ESTEY E, Othus M, Lee SJ, Appelbaum FR, et al
    New drug approvals in acute myeloid leukemia: what's the best end point?
    Leukemia. 2015 Dec 18. doi: 10.1038/leu.2015.
    PubMed     Text format    


  229. PAN MM, Zhang QY, Wang YY, Liu P, et al
    Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway.
    Leukemia. 2015 Dec 17. doi: 10.1038/leu.2015.
    PubMed     Text format    


  230. ZONG H, Sen S, Zhang G, Mu C, et al
    In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche.
    Leukemia. 2015 Dec 16. doi: 10.1038/leu.2015.
    PubMed     Text format    


  231. BHATNAGAR B, Blachly JS, Kohlschmidt J, Eisfeld AK, et al
    Clinical features, and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).
    Leukemia. 2015 Dec 16. doi: 10.1038/leu.2015.
    PubMed     Text format    


  232. MASON CC, Khorashad JS, Tantravahi SK, Kelley TW, et al
    Age-related mutations and chronic myelomonocytic leukemia.
    Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  233. GENTILE M, Shanafelt TD, Cutrona G, Molica S, et al
    A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients.
    Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.
    PubMed     Text format    


  234. TOSELLO V, Bordin F, Yu J, Agnusdei V, et al
    Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein (XIAP) degradation.
    Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  235. RAWSTRON AC, Fazi C, Agathangelidis A, Villamor N, et al
    A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study.
    Leukemia. 2015 Dec 7. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  236. SONG C, Pan X, Ge Z, Gowda C, et al
    Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II (CK2) in leukemia.
    Leukemia. 2015 Dec 7. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  237. ROUCE RH, Shaim H, Sekine T, Weber G, et al
    The TGF-beta/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B acute lymphoblastic leukemia.
    Leukemia. 2015 Dec 1. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


    November 2015
  238. GEYH S, Rodriguez-Paredes M, Jager P, Khandanpour C, et al
    Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia.
    Leukemia. 2015 Nov 25. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  239. SINHA S, Boysen J, Nelson M, Warner SL, et al
    Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.
    Leukemia. 2015 Nov 24. doi: 10.1038/leu.2015.
    PubMed     Text format    


  240. ZABRISKIE MS, Eide CA, Yan D, Vellore NA, et al
    Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format    


  241. DESOUTTER J, Gay J, Berthon C, Ades L, et al
    Molecular prognostic factors in acute myeloid leukemia (AML) receiving first-line therapy with azacitidine.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format    


  242. BALSS J, Thiede C, Bochtler T, Okun JG, et al
    Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  243. CHEN SS, Chang BY, Chang S, Tong T, et al
    BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  244. TARIGHAT SS, Santhanam R, Frankhouser D, Radomska HS, et al
    The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
    Leukemia. 2015 Nov 5. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  245. KOCHER T, Asslaber D, Zaborsky N, Flenady S, et al
    CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.
    Leukemia. 2015 Nov 2. doi: 10.1038/leu.2015.
    PubMed     Text format    


  246. MULLER-TIDOW C, Tschanter P, Rollig C, Thiede C, et al
    Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia.
    Leukemia. 2015 Nov 2. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  247. MORITA K, Masamoto Y, Kataoka K, Koya J, et al
    BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.
    Leukemia. 2015;29:2248-56.
    PubMed     Text format     Abstract available


  248. FORD AM, Mansur MB, Furness CL, van Delft FW, et al
    Protracted dormancy of pre-leukemic stem cells.
    Leukemia. 2015;29:2202-7.
    PubMed     Text format     Abstract available


  249. ZHAO Q, Ahmed M, Tassev DV, Hasan A, et al
    Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
    Leukemia. 2015;29:2238-47.
    PubMed     Text format     Abstract available


  250. MOLENAAR RJ, Thota S, Nagata Y, Patel B, et al
    Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
    Leukemia. 2015;29:2134-42.
    PubMed     Text format     Abstract available


    October 2015
  251. ROSS DM, Altamura HK, Hahn CN, Nicola M, et al
    Delayed diagnosis leading to accelerated phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene.
    Leukemia. 2015 Oct 27. doi: 10.1038/leu.2015.
    PubMed     Text format    


  252. WAKITA S, Yamaguchi H, Ueki T, Usuki K, et al
    Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.
    Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  253. LARRAYOZ M, Blakemore SJ, Dobson RC, Blunt MD, et al
    The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in Chronic Lymphocytic Leukemia cells through downregulation of Mcl-1.
    Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  254. GRATWOHL A, Pfirrmann M, Zander A, Kroger N, et al
    Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment.
    Leukemia. 2015 Oct 14. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  255. NOWEK K, Sun SM, Dijkstra MK, Bullinger L, et al
    Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
    Leukemia. 2015 Oct 14. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  256. BILORI B, Thota S, Clemente MJ, Patel B, et al
    Tofacitinib as a novel salvage therapy for refractory T cell large granular lymphocytic leukemia.
    Leukemia. 2015 Oct 9. doi: 10.1038/leu.2015.
    PubMed     Text format    


  257. ROGERS KA, Ruppert AS, Bingman A, Andritsos LA, et al
    Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
    Leukemia. 2015 Oct 7. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  258. HOCHHAUS A, Rosti G, Cross NC, Steegmann JL, et al
    Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
    Leukemia. 2015 Oct 6. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  259. KIM TH, Yoshida K, Kim YK, Tyndel MS, et al
    Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression.
    Leukemia. 2015 Oct 1. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  260. WATKINS DB, Hughes TP, White DL
    OCT1 and imatinib transport in CML: is it clinically relevant?
    Leukemia. 2015;29:1960-9.
    PubMed     Text format     Abstract available


  261. DEVEAU AP, Forrester AM, Coombs AJ, Wagner GS, et al
    Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease.
    Leukemia. 2015;29:2086-97.
    PubMed     Text format     Abstract available


  262. VASYUTINA E, Boucas JM, Bloehdorn J, Aszyk C, et al
    The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Leukemia. 2015;29:2003-14.
    PubMed     Text format     Abstract available


  263. LI Z, Stolzel F, Onel K, Sukhanova M, et al
    Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.
    Leukemia. 2015;29:2113-6.
    PubMed     Text format    


  264. HAHN CN, Ross DM, Feng J, Beligaswatte A, et al
    A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.
    Leukemia. 2015;29:2101-4.
    PubMed     Text format    


    September 2015
  265. ANDERSSON E, Kuusanmaki H, Bortoluzzi S, Lagstrom S, et al
    Activating somatic mutations outside the SH2-domain of STAT3 in LGL-leukemia.
    Leukemia. 2015 Sep 30. doi: 10.1038/leu.2015.
    PubMed     Text format    


  266. PFIRRMANN M, Baccarani M, Saussele S, Guilhot J, et al
    Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia patients.
    Leukemia. 2015 Sep 29. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  267. CICHOCKI F, Cooley S, Davis Z, DeFor TE, et al
    CD56CD57NKG2C NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.
    Leukemia. 2015 Sep 29. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  268. MARCHAND T, Lamy T, Finel H, Arcese W, et al
    Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation.
    Leukemia. 2015 Sep 22. doi: 10.1038/leu.2015.
    PubMed     Text format    


  269. CHIU YC, Tsai MH, Chou WC, Liu YC, et al
    Prognostic significance of NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia.
    Leukemia. 2015 Sep 16. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  270. ZEIJLEMAKER W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, et al
    Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
    Leukemia. 2015 Sep 16. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  271. ZEIJLEMAKER W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, et al
    A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia.
    Leukemia. 2015 Sep 16. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  272. WIEMELS JL, de Smith AJ, Xiao J, Lee ST, et al
    A functional polymorphism in the CEBPE gene promoter influences acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor Ikaros.
    Leukemia. 2015 Sep 16. doi: 10.1038/leu.2015.
    PubMed     Text format    


  273. WENN K, Tomala L, Wilop S, Vankann L, et al
    Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.
    Leukemia. 2015 Sep 15. doi: 10.1038/leu.2015.
    PubMed     Text format    


  274. LAM CJ, Curtis RE, Dores GM, Engels EA, et al
    Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma.
    Leukemia. 2015 Sep 15. doi: 10.1038/leu.2015.
    PubMed     Text format    


  275. DRIESSEN EM, de Lorenzo P, Campbell M, Felice M, et al
    Outcome of relapsed infant Acute Lymphoblastic Leukemia treated on the interfant-99 protocol.
    Leukemia. 2015 Sep 15. doi: 10.1038/leu.2015.
    PubMed     Text format    


  276. VISCONTE V, Nawrocki ST, Espitia CM, Kelly KR, et al
    Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.
    Leukemia. 2015 Sep 15. doi: 10.1038/leu.2015.
    PubMed     Text format    


  277. MICHEL G, Cunha R, Ruggeri A, O'Brien TA, et al
    Unrelated cord blood transplantation for childhood acute myelogenous leukemia: The influence of cytogenetic risk group stratification.
    Leukemia. 2015 Sep 15. doi: 10.1038/leu.2015.
    PubMed     Text format    


  278. DAVER N, Kantarjian H, Ravandi F, Estey E, et al
    A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Leukemia. 2015 Sep 14. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  279. THIJSSEN R, Ter Burg J, van Bochove GG, de Rooij MF, et al
    The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
    Leukemia. 2015 Sep 4. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  280. BERNAL T, Martinez-Camblor P, Sanchez-Garcia J, de Paz R, et al
    Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
    Leukemia. 2015;29:1875-81.
    PubMed     Text format     Abstract available


  281. BALAKRISHNAN K, Peluso M, Fu M, Rosin NY, et al
    The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Leukemia. 2015;29:1811-22.
    PubMed     Text format     Abstract available


  282. PARRISH C, Scott GB, Migneco G, Scott KJ, et al
    Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.
    Leukemia. 2015;29:1799-810.
    PubMed     Text format     Abstract available


  283. CHANG YI, You X, Kong G, Ranheim EA, et al
    Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Leukemia. 2015;29:1847-56.
    PubMed     Text format     Abstract available


  284. COLES SJ, Gilmour MN, Reid R, Knapper S, et al
    The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.
    Leukemia. 2015;29:1952-4.
    PubMed     Text format    


  285. KARACHUNSKIY A, Roumiantseva J, Lagoiko S, Buhrer C, et al
    Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.
    Leukemia. 2015;29:1955-8.
    PubMed     Text format    


    August 2015
  286. ANTONY-DEBRE I, Duployez N, Bucci M, Geffroy S, et al
    Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.
    Leukemia. 2015 Aug 28. doi: 10.1038/leu.2015.
    PubMed     Text format    


  287. GO RS, Bartley AC, Al-Kali A, Shah ND, et al
    Effect of the type of treatment facility on the outcome of acute myeloid leukemia in the adolescents and young adults.
    Leukemia. 2015 Aug 26. doi: 10.1038/leu.2015.
    PubMed     Text format    


  288. RINGDEN O, Labopin M, Ciceri F, Velardi A, et al
    Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors than with HLA-identical siblings?
    Leukemia. 2015 Aug 21. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  289. TAMBARO FP, Garcia-Manero G, O'Brien SM, Faderl SH, et al
    Outcomes for patients with Chronic Lymphocytic Leukemia (CLL) and Acute leukemia or myelodysplastic syndrome.
    Leukemia. 2015 Aug 20. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  290. DINMOHAMED AG, Szabo A, van der Mark M, Visser O, et al
    Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.
    Leukemia. 2015 Aug 19. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  291. CRISTOBAL I, Manso R, Gonzalez-Alonso P, Rojo F, et al
    Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
    Leukemia. 2015 Aug 18. doi: 10.1038/leu.2015.
    PubMed     Text format    


  292. AKAHANE K, Sanda T, Mansour MR, Radimerski T, et al
    HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
    Leukemia. 2015 Aug 12. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  293. NISHIOKA C, Ikezoe T, Takeuchi A, Nobumoto A, et al
    The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells.
    Leukemia. 2015 Aug 11. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  294. STREFFORD JC, Kadalayil L, Forster J, Mjj RZ, et al
    Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
    Leukemia. 2015 Aug 10. doi: 10.1038/leu.2015.
    PubMed     Text format    


  295. ESWARAN J, Sinclair P, Heidenreich O, Irving J, et al
    The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.
    Leukemia. 2015;29:1623-31.
    PubMed     Text format     Abstract available


  296. SANDEN C, Gullberg U
    The DEK oncoprotein and its emerging roles in gene regulation.
    Leukemia. 2015;29:1632-6.
    PubMed     Text format     Abstract available


  297. HYDE RK, Zhao L, Alemu L, Liu PP, et al
    Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
    Leukemia. 2015;29:1771-8.
    PubMed     Text format     Abstract available


  298. GAO XN, Yan F, Lin J, Gao L, et al
    AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation.
    Leukemia. 2015;29:1730-40.
    PubMed     Text format     Abstract available


  299. LU L, Saunders VA, Leclercq TM, Hughes TP, et al
    Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells.
    Leukemia. 2015;29:1792-4.
    PubMed     Text format    


  300. MORA-JENSEN H, Jendholm J, Rapin N, Andersen MK, et al
    Cellular origin of prognostic chromosomal aberrations in AML patients.
    Leukemia. 2015;29:1785-9.
    PubMed     Text format    


  301. CHEN X, Newell LF, Xie H, Walter RB, et al
    Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.
    Leukemia. 2015;29:1779-80.
    PubMed     Text format    


    July 2015
  302. JENKINSON S, Kirkwood AA, Goulden N, Vora A, et al
    Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.
    Leukemia. 2015 Jul 29. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  303. BALBACH ST, Makarova O, Bonn BR, Zimmermann M, et al
    Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia.
    Leukemia. 2015 Jul 28. doi: 10.1038/leu.2015.
    PubMed     Text format    


  304. RONCERO AM, Lopez-Nieva P, Cobos-Fernandez MA, Villa-Morales M, et al
    Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.
    Leukemia. 2015 Jul 28. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  305. VISHWAKARMA BA, Nguyen N, Makishima H, Hosono N, et al
    Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development.
    Leukemia. 2015 Jul 24. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  306. EIRING AM, Khorashad JS, Anderson DJ, Yu F, et al
    beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
    Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  307. BOER JM, van der Veer A, Rizopoulos D, Fiocco M, et al
    Prognostic value of rare IKZF1 deletion in childhood b-cell precursor acute lymphoblastic leukemia: an international collaborative study.
    Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  308. TAN SH, Yam AW, Lawton LN, Wong RW, et al
    TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia.
    Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.
    PubMed     Text format    


  309. CERVERA N, Carbuccia N, Garnier S, Guille A, et al
    Molecular characterization of acute erythroid leukemia (M6-AML) usingtargeted next-generation sequencing.
    Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.
    PubMed     Text format    


  310. DINMOHAMED AG, Visser O, van Norden Y, Blijlevens NM, et al
    Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.
    Leukemia. 2015 Jul 17. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  311. CHIN DW, Watanabe-Okochi N, Wang CQ, Tergaonkar V, et al
    Mouse models for CBF leukemia.
    Leukemia. 2015 Jul 13. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  312. WU H, Hu C, Wang A, Weisberg EL, et al
    Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
    Leukemia. 2015 Jul 13. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  313. POZZO F, Bittolo T, Arruga F, Bulian P, et al
    NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation.
    Leukemia. 2015 Jul 13. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  314. CROSS NC, Muller MC, Hochhaus A
    Response to Ho-Wan Ip and Chi-Chiu.
    Leukemia. 2015;29:1619.
    PubMed     Text format    


  315. METZELDER SK, Michel C, von Bonin M, Rehberger M, et al
    NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Leukemia. 2015;29:1470-7.
    PubMed     Text format     Abstract available


  316. MOHTY M, Malard F
    To RIC or not to RIC: that is the question.
    Leukemia. 2015;29:1450-1.
    PubMed     Text format    


  317. LUCAS CM, Harris RJ, Holcroft AK, Scott LJ, et al
    Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
    Leukemia. 2015;29:1514-23.
    PubMed     Text format     Abstract available


  318. YOUNG AL, Wong TN, Hughes AE, Heath SE, et al
    Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing.
    Leukemia. 2015;29:1608-11.
    PubMed     Text format    


  319. RUSSELL NH, Kjeldsen L, Craddock C, Pagliuca A, et al
    A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia.
    Leukemia. 2015;29:1478-84.
    PubMed     Text format     Abstract available


    June 2015
  320. HUGHES TP, Saglio G, Quintas-Cardama A, Mauro MJ, et al
    BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
    Leukemia. 2015 Jun 29. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  321. KODE A, Mosialou I, Manavalan SJ, Rathinam CV, et al
    FoxO1-Dependent induction of acute myeloid leukemia by osteoblasts in mice.
    Leukemia. 2015 Jun 25. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  322. ZASSADOWSKI F, Pokorna K, Ferre N, Guidez F, et al
    Lithium Chloride antileukemic activity in Acute Promyelocytic Leukemia is GSK-3 and MEK/ERK dependent.
    Leukemia. 2015 Jun 25. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  323. DURINCK K, Loocke WV, der Meulen JV, de Walle IV, et al
    Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.
    Leukemia. 2015 Jun 25. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  324. DE LEEUW DC, Verhagen HJ, Denkers F, Kavelaars FG, et al
    MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.
    Leukemia. 2015 Jun 25. doi: 10.1038/leu.2015.
    PubMed     Text format    


  325. ALSADEQ A, Strube S, Krause S, Carlet M, et al
    Effects of p38alpha/beta inhibition on acute lymphoblastic leukemia (ALL) proliferation and survival in vivo.
    Leukemia. 2015 Jun 24. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  326. CASTAGNETTI F, Gugliotta G, Breccia M, Stagno F, et al
    Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
    Leukemia. 2015 Jun 19. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  327. PARK IK, Mundy-Bosse B, Whitman SP, Zhang X, et al
    Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Leukemia. 2015 Jun 19. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  328. SOOD R, Hansen NF, Donovan FX, Carrington B, et al
    Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia.
    Leukemia. 2015 Jun 15. doi: 10.1038/leu.2015.
    PubMed     Text format    


  329. LANDBERG N, Hansen N, Askmyr M, Agerstam H, et al
    IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
    Leukemia. 2015 Jun 12. doi: 10.1038/leu.2015.
    PubMed     Text format    


  330. KHODADOUST MS, Luo B, Medeiros BC, Johnson RC, et al
    Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed phenotype acute leukemia.
    Leukemia. 2015 Jun 9. doi: 10.1038/leu.2015.
    PubMed     Text format    


  331. WEDEH G, Cerny-Reiterer S, Eisenwort G, Herrmann H, et al
    Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia.
    Leukemia. 2015 Jun 9. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  332. DORRANCE AM, Neviani P, Ferenchak GJ, Huang X, et al
    Targeting leukemia stem cells in vivo with ANTAGOMIR-126 nanoparticles in acute myeloid leukemia.
    Leukemia. 2015 Jun 9. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  333. CLAPPIER E, Grardel N, Bakkus M, Rapion J, et al
    IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
    Leukemia. 2015 Jun 8. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  334. FORSTER VJ, Nahari MH, Martinez-Soria N, Bradburn AK, et al
    The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype.
    Leukemia. 2015 Jun 8. doi: 10.1038/leu.2015.
    PubMed     Text format    


  335. HOFFMANN VS, Baccarani M, Hasford J, Lindoerfer D, et al
    The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
    Leukemia. 2015;29:1336-43.
    PubMed     Text format     Abstract available


  336. BURNETT AK, Russell N, Hills RK, Panoskaltsis N, et al
    A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.
    Leukemia. 2015;29:1312-9.
    PubMed     Text format     Abstract available


  337. WANG LD, Rao TN, Rowe RG, Nguyen PT, et al
    The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy.
    Leukemia. 2015;29:1320-30.
    PubMed     Text format     Abstract available


  338. SPENCER DH, Young MA, Lamprecht TL, Helton NM, et al
    Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells.
    Leukemia. 2015;29:1279-89.
    PubMed     Text format     Abstract available


  339. CHAE HD, Mitton B, Lacayo NJ, Sakamoto KM, et al
    Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA.
    Leukemia. 2015;29:1379-89.
    PubMed     Text format     Abstract available


  340. FISKUS W, Sharma S, Saha S, Shah B, et al
    Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.
    Leukemia. 2015;29:1267-78.
    PubMed     Text format     Abstract available


  341. MOTIWALA T, Kutay H, Zanesi N, Frissora FW, et al
    PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Leukemia. 2015;29:1350-9.
    PubMed     Text format     Abstract available


    May 2015
  342. ROMERO PV, Cialfi S, Palermo R, De Blasio C, et al
    The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha.
    Leukemia. 2015 May 18. doi: 10.1038/leu.2015.
    PubMed     Text format    


  343. TOKUMASU M, Murata C, Shimada A, Ohki K, et al
    Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese pediatric leukemia/lymphoma study group AML-05 trial.
    Leukemia. 2015 May 15. doi: 10.1038/leu.2015.
    PubMed     Text format    


  344. BLUME CJ, Hotz-Wagenblatt A, Hullein J, Sellner L, et al
    p53-dependent non-coding RNA networks in Chronic Lymphocytic Leukemia.
    Leukemia. 2015 May 14. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  345. KHALIFE J, Radomska HS, Santhanam R, Huang X, et al
    Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Leukemia. 2015 May 14. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  346. KALMANTI L, Saussele S, Lauseker M, Muller MC, et al
    Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
    Leukemia. 2015;29:1123-32.
    PubMed     Text format     Abstract available


  347. JO A, Mitani S, Shiba N, Hayashi Y, et al
    High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.
    Leukemia. 2015;29:1076-83.
    PubMed     Text format     Abstract available


  348. GUINN D, Ruppert AS, Maddocks K, Jaglowski S, et al
    miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
    Leukemia. 2015;29:1210-3.
    PubMed     Text format    


  349. MIAN AA, Rafiei A, Haberbosch I, Zeifman A, et al
    PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Leukemia. 2015;29:1104-14.
    PubMed     Text format     Abstract available


  350. TE RAA GD, Derks IA, Navrkalova V, Skowronska A, et al
    The impact of SF3B1 mutations in CLL on the DNA-damage response.
    Leukemia. 2015;29:1133-42.
    PubMed     Text format     Abstract available


  351. STAFFAS A, Karlsson C, Persson M, Palmqvist L, et al
    Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
    Leukemia. 2015;29:1032-40.
    PubMed     Text format     Abstract available


    April 2015
  352. POGLIO S, Cahu X, Uzan B, Besnard-Guerin C, et al
    Rapid childhood T-ALL growth in xenograft models correlates with mature phenotype and NF-kappaB pathway activation but not with poor prognosis.
    Leukemia. 2015;29:977-80.
    PubMed     Text format    


  353. ORTEGA M, Bhatnagar H, Lin AP, Wang L, et al
    A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.
    Leukemia. 2015;29:968-76.
    PubMed     Text format     Abstract available


  354. INOUE D, Kitaura J, Matsui H, Hou HA, et al
    SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Leukemia. 2015;29:847-57.
    PubMed     Text format     Abstract available


  355. TURSKY ML, Beck D, Thoms JA, Huang Y, et al
    Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.
    Leukemia. 2015;29:819-27.
    PubMed     Text format     Abstract available


  356. SHIELDS BJ, Alserihi R, Nasa C, Bogue C, et al
    Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
    Leukemia. 2015;29:927-38.
    PubMed     Text format     Abstract available


  357. STEGER J, Fuller E, Garcia-Cuellar MP, Hetzner K, et al
    Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.
    Leukemia. 2015;29:901-8.
    PubMed     Text format     Abstract available


  358. CHENG S, Guo A, Lu P, Ma J, et al
    Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
    Leukemia. 2015;29:895-900.
    PubMed     Text format     Abstract available


  359. KAMEL S, Horton L, Ysebaert L, Levade M, et al
    Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
    Leukemia. 2015;29:783-7.
    PubMed     Text format     Abstract available


    March 2015
  360. GALE RP
    Reduced-Intensity transplants, conventional transplants or chemotherapy for acute myeloid leukemia in 1st remission: who knows; ask your wife?
    Leukemia. 2015 Mar 24. doi: 10.1038/leu.2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: